A Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

115 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-29

Study Completion Date

2022-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate the safety and immunogenicity profile of of a novel nasal spray investigational vaccine, which is a potential prophylactic vaccine for current pandemic disease COVID-19.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Evaluate Safety & Immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 for COVID-19 in Healthy Adults Received 2 Doses of BNT162b2

NCT05200741

Covid19

UNKNOWN PHASE2

The Safety and Tolerability of A8G6 COVID-19 Neutralization Antibody Combined With Nasal Spray

NCT06127498

SARS-CoV-2 Prevention

UNKNOWN NA

NasoShield in Healthy Adults to Study Safety and Immunogenicity

NCT04415749

Healthy Volunteers

COMPLETED PHASE1

NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)

NCT04442230

Coronavirus Infection

TERMINATED PHASE2

A Study of Intranasal ChAdOx1 nCOV-19

NCT04816019

Coronavirus

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, double-blinded, placebo-controlled study which comprises two parts, (dose escalation part and dose expansion part), and each volunteer will only be invited to join either one part. The duration of each part is around one (1) year, including screening, dosing and follow up visits.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test Product

DelNS1-nCoV-RBD LAIV at 1×107 EID50 and 1×107.7 EID50, 2 doses 4 weeks apart, intranasal administration

Group Type EXPERIMENTAL

DelNS1-nCoV-RBD LAIV

Intervention Type BIOLOGICAL

Genetically engineered live attenuated influenza virus to express the receptor binding domain of SARS-CoV-2's spike protein for triggering human body's immune responses against SARS-CoV-2

Reference Product

Matching placebo, 2 doses 4 weeks apart, intranasal administration

Group Type PLACEBO_COMPARATOR

Matching placebo

Intervention Type BIOLOGICAL

0.9% NaCl solution

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DelNS1-nCoV-RBD LAIV

Genetically engineered live attenuated influenza virus to express the receptor binding domain of SARS-CoV-2's spike protein for triggering human body's immune responses against SARS-CoV-2

Intervention Type BIOLOGICAL

Matching placebo

0.9% NaCl solution

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Informed Consent: The subject (or the subject's legally acceptable representative, if applicable) must be capable of giving written informed consent and, prior to the commencement of any study-specific procedure, must sign an ICF indicating the consent on the subject's voluntary participation in the study and compliance with the requirements and restrictions listed on the ICF.
2. Gender and Age: Male or female, at the age of ≥ 18 and ≤ 55 on the day of signing the ICF.
3. Body Weight and BMI: Body weight ≥ 50 kg and BMI ≥ 18.5 kg/m2 and \< 25 kg/m2 at screening and baseline.
4. Medical Conditions or Diagnoses: Existence of all of the following medical conditions or diagnoses:

1. Generally in good health with no clinically significant abnormality, as determined by medical history, physical examination, 12-lead ECG and clinical laboratory tests at screening and baseline;
2. Normal vital signs at screening and baseline, as defined by:

* Body (tympanic) temperature ≤ 37.5oC;
* Resting pulse rate ≥ 50 and ≤ 100 bpm; and
* DBP ≥ 50 and ≤ 90 mmHg and SBP ≥ 90 and ≤ 140 mmHg.
5. Contraception: Willingness and agreement to undertake measures to avoid pregnancy of the subject or the subject's sexual partner(s) as detailed below:

1. A female subject who is a woman of childbearing potential (WOCBP) must be willing and agree to remain abstinent or practise at least one effective contraceptive method from at least 30 days prior to the first vaccination until 60 days after the second vaccination;
2. A male subject (i) who is sexually active with a WOCBP (except who is permanently sterile by bilateral orchiectomy or vasectomy) must be willing and agree to remain abstinent or practise at least one effective contraceptive method from the first vaccination until 60 days after the second vaccination; and (ii) must be willing and agree to refrain from sperm donation during the aforesaid period.
6. Breastfeeding: A female subject must be willing and agree to avoid engagement in breastfeeding at any time from the first vaccination until 60 days after the second vaccination.
7. Blood Donation: Willingness and agreement to avoid blood donation from screening to the end of the period of participation in this study.

Exclusion Criteria

1. Medical History: History of any of the following diseases or conditions:

1. COVID-19;
2. SARS;
3. Any significant respiratory diseases (e.g. COPD, asthma);
4. Any significant cardiovascular disease (e.g. angina, cardiac arrhythmias);
5. Blood dyscrasias or any significant disorder of coagulation;
6. Any chronic liver disease (e.g. autoimmune hepatitis and cirrhosis);
7. Any chronic infection (e.g. hepatitis B, hepatitis C and HIV);
8. Any malignant neoplastic disease;
9. Encephalopathy, neuropathy or unstable central nervous system (CNS) pathology;
10. Any psychiatric disorder, psychotic disorder, major affective disorder or suicidal ideation;
11. Any immunodeficiency or autoimmune disease;
12. Any severe allergic reaction (e.g. anaphylaxis) to any vaccine or substance, which requires hospitalization or emergency medical care;
13. Any hypersensitivity to (especially anaphylactic reactions) to eggs, egg proteins or gentamicin sulfate;
14. Any chronic rhinitis, nasal septal defect, cleft palate, nasal polyps or other nasal abnormality that might affect vaccine administration;
15. History of alcohol or illicit drug abuse, or used any illicit drug within 6 months prior to screening.
2. Medical Conditions or Diagnoses: Existence of any of the following medical conditions or diagnoses:

1. Positive serum pregnancy test at screening or positive urine pregnancy test at baseline (for WOCBP);
2. IgE level \> 1,000 U.I./ml at screening;
3. Positive SARS-CoV-2 test result in serum, deep throat saliva (DTS) or nasopharyngeal swab (NPS) within 4 days prior to baseline;
4. T3, T4 or TSH \< LLN or \> ULN at screening;
5. Positive HIV test result at screening;
6. Positive HBsAg test result at screening;
7. Positive HCV antibody test result at screening;
8. Positive T-cell interferon-γ release assay (TIGRA) result (i.e. by QuantiFERON®-TB Gold Plus™ test) at screening (Remark: A single repeat will be allowed with an indeterminate result);
9. Positive urine drug screen test result or positive blood alcohol test result at screening or baseline;
10. Any clinically significant findings (e.g. active or acute cardiac/pulmonary diseases) from chest X-ray examination performed at or within 4 months prior to screening.
3. Prior/Concomitant Interventions: Use of or undergoing any of the following prior or concomitant medications, therapies or interventions:

1. Any COVID-19 or coronavirus vaccine at any time prior to the first vaccination, or planned use of any such vaccine throughout the study;
2. Any vaccine other than COVID-19 or coronavirus vaccines within 28 days prior to the first vaccination, or planned use of any such vaccine up to 28 days after the second vaccination;
3. Any immune-modifying medication/therapy (e.g. immunomodulator and immunosuppressant) within 6 months prior to the first vaccination, or planned use of any such medication/therapy throughout the study;
4. Any blood product (including blood transfusion) or immunoglobulin within 3 months prior to the first vaccination, or planned use of any such therapy throughout the study;
5. Any anticoagulation medication within 28 days prior to the first vaccination, or planned use of any such medication up to 28 days after the second vaccination;
6. Any psychotropic medication within 28 days prior to the first vaccination, or planned use of any such medication up to 28 days after the second vaccination;
7. Regular use of any inhaled/nebulized corticosteroid;
8. Any intranasal preparation within 48 hours prior to the first vaccination, or planned use of any such preparation up to 48 hours after the second vaccination;
9. Any influenza antiviral medication within 48 hours prior to the first vaccination, or planned use of any such medication up to 14 days after the second vaccination;
10. Any prescription or over-the-counter medication or supplement product (e.g. vitamin, dietary supplement, herbal preparation) within 7 days prior to the first vaccination, unless with the investigator's approval for managing a chronic condition;
11. Donated ≥ 450 ml of blood within 28 days prior to the first vaccination;
12. Prior nasal surgery or nasal cauterization.
4. Prior/Concurrent Clinical Study: Prior or concurrent participation in any other clinical study, including:

1. Prior or current participation in another COVID-19 vaccine study;
2. Prior participation in any interventional clinical study and use of any investigational intervention within 90 days prior to the first vaccination;
3. Concurrent participation or plan for participation in another interventional clinical study during participation in this study.
5. Other Significant Medical Conditions: Any clinically significant concomitant disease or condition that, in the reasonable opinion of the investigator, may interfere with the subject's participation in this study or pose an unacceptable safety risk for the subject's participation in this study.
6. Special Conditions: Existence of any of the following special conditions:

1. Close contact with anyone known to have COVID-19 within 30 days prior to the first vaccination;
2. Travelled outside Hong Kong within 14 days prior to the first vaccination;
3. Planned to travel outside Hong Kong at any time during the period from screening to Day 57(±3) visit.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes